IAG Strengthens Team with New Appointments in the European and North American Offices
IAG, Image Analysis Group announced today the expansion of its executive management team in London, UK and Philadelphia, USA offices and welcomed Dr. Boubakeur Belaroussi as Head of Product, Maartje Meijer as Head of Operations, Frank Cerrone as a lead MRI Technologist and Yeda Ford as a Head of Commercial Operations.
Dr. Boubakeur Belaroussi, passionate about improving business processes using data-driven technologies (machine learning, IA, Data Science, Predictive Analytics) joins the IAG’s London office after spending over 12 years in clinical research, handling healthcare projects in information system development in both start-up and global companies. Bouba will lead the team furthering the development of IAG’s proprietary development platform DYNAMIKA and managing complex projects and clinical trial programs, collaborating with cross-functional teams and focusing the teams on our bio-pharmaceutical partners development goals.
Maartje Meijere’s earlier experience at one of the top clinical research organizations will bolster support the IAG global operations team in its phase I to III clinical trials in musculoskeletal, oncology and rare disease therapeutic areas.
Frank Cerrone joins IAG’s new team in Philadelphia, PA, USA where he will be responsible for providing oversight to clinical teams on several different assessment criteria including RAMRIS, PSAMRIS, Immune-Related Response Criteria (irRC), and Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and RANO criteria and advanced quantitatve medtholgies, which we bring to early stage clinical development programs. Franks brings over 25 years as an MRI technologist working in clinical research studies in oncology and rheumatology.
Yeda Ford joins IAG as a Head of Commercial Operations to oversee IAG’s bio-partnering program and the team of analysts with the focus on expanding IAG relationships with ambitious biotechnologies companies developing novel treatments to address unmet patient needs.
“Not many jobs offer an opportunity to change people’s lives. We are delighted to welcome Yeda, Frank, Maartje and Bouba who share our passion for IAG’s vision and bio-pharmaceutical focus combined with years of experience in the industry,” says Dr. Olga Kubassova, IAG CEO.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.
Dr Kubassova is a leading innovator and passionate investor in healthcare.
Presenting new data from Ulcerative Colitis trial at DDW 2023.